



Prior Authorization Process for Synagis®

Background

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Its safety and efficacy were established in children with bronchopulmonary dysplasia, infants with a history of premature birth (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease.¹

RSV Season and Synagis Availability

RSV surveillance data suggests that there is a distinct seasonal peak for RSV activity, which for most of the country typically occurs between November and March, but it may vary by region. Synagis doses will be available from September through March.

Prior Authorization Requirements for Synagis

Prior authorization is *required* for outpatient treatment with Synagis. Here's how to request authorization to avoid delays in treatment for members:

- Please complete and fax the Synagis worksheet, also known as an enrollment form, to our Pharmacy Prior Authorization Department at **866-940-7328**. The form is available at **UHCCommunityPlan.com > For Health Care Professionals > Hawaii > Pharmacy Program**.
- We use the most current Synagis guidelines released by the American Academy of Pediatrics and its Committee on Infectious Diseases for coverage decisions.^{2,3}
- We will notify you by fax of the decision regarding your request for authorization.
- If the request is approved, we will coordinate delivery of Synagis through our contracted specialty pharmacy provider, BriovaRx. If you have questions about the delivery of Synagis, please contact BriovaRx at **888-293-9309**, option 1.

To avoid delays, please fax **all** prior authorization requests to our pharmacy prior authorization department at **866-940-7328**.

If you have questions, please call our Pharmacy Prior Authorization Department at **800-310-6826**. Thank you.

1. Product information. Synagis™ (palivizumab). MedImmune, Inc.

2. AAP updates guidance on use of palivizumab for RSV prophylaxis (Policy Statement). AAP News 2014; 35:8 1.

3. AAP updates guidance on use of palivizumab for RSV prophylaxis (Technical Report). AAP News 2014; 35:8 1.